TAK
Income statement / Annual
Last year (2023), Takeda Pharmaceutical Company Limited's total revenue was $4.26 T,
an increase of 5.87% from the previous year.
In 2023, Takeda Pharmaceutical Company Limited's net income was $144.07 B.
See Takeda Pharmaceutical Company Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$4.26 T
|
$4.03 T
|
$3.57 T
|
$3.20 T
|
$3.29 T
|
$2.10 T
|
$1.77 T
|
$1.73 T
|
$1.81 T
|
$1.78 T
|
| Cost of Revenue |
$1.43 T |
$1.24 T |
$1.11 T |
$994.31 B |
$1.09 T |
$659.69 B |
$495.92 B |
$558.76 B |
$535.41 B |
$520.99 B |
| Gross Profit |
$2.83 T |
$2.78 T |
$2.46 T |
$2.20 T |
$2.20 T |
$1.44 T |
$1.27 T |
$1.17 T |
$1.27 T |
$1.26 T |
| Gross Profit Ratio |
0.66 |
0.69 |
0.69 |
0.69 |
0.67 |
0.69 |
0.72 |
0.68 |
0.7 |
0.71 |
| Research and Development
Expenses |
$729.92 B
|
$633.33 B
|
$526.09 B
|
$455.83 B
|
$492.38 B
|
$368.30 B
|
$325.44 B
|
$312.30 B
|
$345.93 B
|
$382.10 B
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$499.40 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$113.21 B
|
| Selling, General &
Administrative Expenses |
$1.05 T
|
$997.31 B
|
$886.36 B
|
$875.66 B
|
$964.74 B
|
$717.60 B
|
$628.11 B
|
$619.06 B
|
$650.77 B
|
$612.61 B
|
| Other Expenses |
$834.44 B |
-$9.47 B |
$588.87 B |
$1.41 T |
$1.43 T |
$908.87 B |
$707.38 B |
$705.13 B |
$795.22 B |
$1.00 T |
| Operating Expenses |
$2.62 T |
$2.29 T |
$2.00 T |
$1.69 T |
$2.10 T |
$1.28 T |
$1.03 T |
$1.02 T |
$1.14 T |
$1.39 T |
| Cost And Expenses |
$4.05 T |
$3.54 T |
$3.11 T |
$2.69 T |
$3.19 T |
$1.94 T |
$1.53 T |
$1.58 T |
$1.68 T |
$1.91 T |
| Interest Income |
$11.29 B |
$62.91 B |
$23.70 B |
$105.52 B |
$27.83 B |
$6.62 B |
$39.54 B |
$12.27 B |
$21.65 B |
$15.36 B |
| Interest Expense |
$153.63 B |
$169.70 B |
$166.61 B |
$248.63 B |
$165.01 B |
$48.16 B |
$31.93 B |
$23.25 B |
$31.93 B |
$32.88 B |
| Depreciation &
Amortization |
$728.00 B
|
$664.40 B
|
$583.15 B
|
$559.67 B
|
$583.65 B
|
$247.69 B
|
$182.13 B
|
$171.43 B
|
$197.38 B
|
$260.95 B
|
| EBITDA |
$874.60 B
|
$1.18 T
|
$1.18 T
|
$983.72 B
|
$880.33 B
|
$464.22 B
|
$359.96 B
|
$296.88 B
|
$349.85 B
|
$57.29 B
|
| EBITDA Ratio |
0.21 |
0.3 |
0.29 |
0.37 |
0.21 |
0.18 |
0.24 |
0.22 |
0.19 |
0.08 |
| Operating Income Ratio
|
0.05
|
0.12
|
0.13
|
0.16
|
0.03
|
0.1
|
0.14
|
0.09
|
0.07
|
-0.07
|
| Total Other
Income/Expenses Net |
-$161.28 B
|
-$115.42 B
|
-$158.27 B
|
-$143.03 B
|
-$161.16 B
|
-$110.07 B
|
-$24.58 B
|
-$12.52 B
|
-$10.29 B
|
-$16.18 B
|
| Income Before Tax |
$52.79 B |
$375.09 B |
$302.57 B |
$366.24 B |
-$60.75 B |
$94.90 B |
$217.21 B |
$143.35 B |
$120.54 B |
-$145.44 B |
| Income Before Tax Ratio
|
0.01
|
0.09
|
0.08
|
0.11
|
-0.02
|
0.05
|
0.12
|
0.08
|
0.07
|
-0.08
|
| Income Tax Expense |
-$91.41 B |
$58.05 B |
$72.41 B |
-$9.94 B |
-$105.04 B |
-$14.12 B |
$30.50 B |
$27.83 B |
$37.06 B |
-$2.40 B |
| Net Income |
$144.07 B |
$317.02 B |
$230.06 B |
$376.01 B |
$44.24 B |
$109.13 B |
$186.89 B |
$114.94 B |
$80.17 B |
-$145.78 B |
| Net Income Ratio |
0.03 |
0.08 |
0.06 |
0.12 |
0.01 |
0.05 |
0.11 |
0.07 |
0.04 |
-0.08 |
| EPS |
92.09 |
204.29 |
147.14 |
240.72 |
28.41 |
69.57 |
239.35 |
147.15 |
102.26 |
-92.94 |
| EPS Diluted |
91.16 |
201.94 |
145.87 |
238.96 |
28.25 |
69.57 |
237.55 |
146.26 |
101.71 |
-92.94 |
| Weighted Average Shares
Out |
$1.56 B
|
$1.55 B
|
$1.56 B
|
$1.56 B
|
$1.56 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
| Weighted Average Shares
Out Diluted |
$1.58 B
|
$1.57 B
|
$1.58 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
$1.57 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
